ara-GTP accumulation in T-lymphoblasts

"ara-GTP accumulation in T-lymphoblasts" is not a molecular target, receptor, enzyme, or protein. Instead, it describes a biochemical effect or pharmacological phenomenon: the buildup of the active metabolite ara-GTP (arabinosylguanine triphosphate) in T-lymphoblasts (a type of immature T cell) following treatment with nelarabine or its active metabolite ara-G. This accumulation is a crucial determinant of nelarabine’s antileukemic selectivity for T-lymphoblastic leukemia, and it underlies the cytotoxic effect of the drug on these cells. Mechanistically, after nelarabine is metabolized to ara-G, sequential phosphorylation steps convert it to ara-GTP, which preferentially accumulates in T-lymphoblasts due to higher activity of kinases such as deoxycytidine kinase in these cells. The incorporated ara-GTP then interferes with DNA synthesis and repair, inducing apoptosis, particularly in dividing T-lineage cells. However, "ara-GTP accumulation in T-lymphoblasts" is not a receptor, enzyme, transporter, or another molecular entity; it is a cellular effect, not a druggable target or molecular species itself. If you are seeking information on the relevant therapeutic target, more specific targets include: The metabolic enzymes involved in activation (such as deoxyguanosine kinase, deoxycytidine kinase), the DNA of T-lymphoblasts (where ara-GTP is incorporated), possibly metabolic regulators like SAMHD1, known to affect ara-GTP levels and leukemic sensitivity. In short, "ara-GTP accumulation in T-lymphoblasts" describes a pharmacodynamic outcome and is not itself a canonical therapeutic target, receptor, or molecular entity.

Following nelarabine/ara-G administration, sequential phosphorylation converts ara-G to ara-GTP, which accumulates in T-lymphoblasts due to high kinase activity (e.g., deoxycytidine kinase). The incorporated ara-GTP then interferes with DNA synthesis and repair, leading to apoptosis.